125 related articles for article (PubMed ID: 7046903)
1. The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bertotto A; Spinozzi F; Bracaglia AM; Falini B; Davis S
Cancer; 1982 Aug; 50(3):490-7. PubMed ID: 7046903
[TBL] [Abstract][Full Text] [Related]
2. The in vitro effect of a calf thymus extract (thymostimulin) on the immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bracaglia AM; Ballatori E; Davis S
Cancer; 1982 Jan; 49(2):245-50. PubMed ID: 7053826
[TBL] [Abstract][Full Text] [Related]
3. The in vivo effect of thymic factor (thymostimulin) administration in Hodgkin's disease patients. Correlation of skin reactivity and leukocyte migration-inhibition factor in the sera of anergic subjects.
Velardi A; Rambotti P; Cernetti C; Spinozzi F; Bertotto A; Martelli MF
Thymus; 1983 Sep; 5(5-6):429-32. PubMed ID: 6362105
[TBL] [Abstract][Full Text] [Related]
4. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.
Velardi A; Spinozzi F; Rambotti P; Tabilio A; Losito A; Zampi I; Cernetti C; Martelli MF; Grignani F; Davis S
J Clin Oncol; 1983 Feb; 1(2):117-25. PubMed ID: 6668495
[TBL] [Abstract][Full Text] [Related]
5. Immunorestorative properties of thymostimulin (TS) in patients with Hodgkin's disease in clinical remission.
Liberati AM; Brugia M; Edwards BS; Bertoni P; Ballatori E; Puxeddu A; Grignani F
Cancer Immunol Immunother; 1985; 19(2):136-41. PubMed ID: 3872709
[TBL] [Abstract][Full Text] [Related]
6. E-rosette inhibiting substance in Hodgkin's disease spleen extracts.
Bieber MM; Fuks Z; Kaplan HS
Clin Exp Immunol; 1977 Sep; 29(3):369-75. PubMed ID: 201408
[TBL] [Abstract][Full Text] [Related]
7. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
[TBL] [Abstract][Full Text] [Related]
8. In vitro lymphocyte dysfunction in Hodgkin's disease.
Graze PR; Perlin E; Royston I
J Natl Cancer Inst; 1976 Feb; 56(2):239-43. PubMed ID: 130496
[TBL] [Abstract][Full Text] [Related]
9. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
[TBL] [Abstract][Full Text] [Related]
10. Effect of thymic extract on blastogenic responses of chickens.
Murthy KK; Ragland WL
Poult Sci; 1992 Feb; 71(2):311-5. PubMed ID: 1546041
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between skin reactivity and T lymphocytes and monocytes in Hodgkin's disease.
Müftüoğlu AU; Yalçin B
Acta Haematol; 1980; 63(5):286-8. PubMed ID: 6774558
[TBL] [Abstract][Full Text] [Related]
12. Five-year survival in Hodgkin's disease. The prospective value of immune status at diagnosis.
van Rijswijk RE; de Meijer A; Sybesma JP; Kater L
Cancer; 1986 Apr; 57(8):1489-96. PubMed ID: 2936444
[TBL] [Abstract][Full Text] [Related]
13. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
Land JM; Litwin J; Bigel P; Oberling F; Mayer S
Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
[TBL] [Abstract][Full Text] [Related]
14. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
Levo Y; Rotter V; Ramot B
Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
[TBL] [Abstract][Full Text] [Related]
15. Immune status of untreated patients with Hodgkin's disease and prognosis.
Björkholm M; Wedelin C; Holm G; Ogenstad S; Johansson B; Mellstedt H
Cancer Treat Rep; 1982 Apr; 66(4):701-9. PubMed ID: 7074640
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission.
Liberati AM; Ballatori E; Fizzotti M; Schippa M; Cini L; Cinieri S; Proietti MG; Di Marzio R; Senatore M; Grignani F
Cancer Immunol Immunother; 1988; 26(1):87-93. PubMed ID: 3125973
[TBL] [Abstract][Full Text] [Related]
17. TFX immunotherapy in children with ALL during remission.
Traczewska M; Chmielewska D; Ochocka M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(4):525-36. PubMed ID: 2414181
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of T and B lymphocytes and cellular immune function in Hodgkin's disease.
Bobrove AM; Fuks Z; Strober S; Kaplan HS
Cancer; 1975 Jul; 36(1):169-79. PubMed ID: 54208
[TBL] [Abstract][Full Text] [Related]
19. The in vitro effect of a calf thymus extract (thymostimulin) on T cell phenotypes in cord blood lymphocytes.
Velardi A; Gerli R; Rambotti P; Spinozzi F; Cernetti C; Angelini A; Martelli MF
Am J Reprod Immunol (1980); 1982 Oct; 2(5):250-3. PubMed ID: 6217758
[TBL] [Abstract][Full Text] [Related]
20. The influence of splenectomy on cellular immunologic parameters in Hodgkin's disease.
Wagener DJ; Geestman E; Borgonjen A; Haanen C
Cancer; 1976 May; 37(5):2212-9. PubMed ID: 130968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
